vs
Atmus Filtration Technologies Inc.（ATMU）与拜玛林制药（BMRN）财务数据对比。点击上方公司名可切换其他公司
拜玛林制药的季度营收约是Atmus Filtration Technologies Inc.的2.0倍（$874.6M vs $446.6M），Atmus Filtration Technologies Inc.净利率更高（10.7% vs -5.3%，领先16.1%），拜玛林制药同比增速更快（17.0% vs 9.8%），拜玛林制药自由现金流更多（$58.9M vs $31.2M），过去两年拜玛林制药的营收复合增速更高（16.1% vs 2.3%）
Atmus过滤技术公司是一家专业过滤解决方案提供商，研发、生产和销售空气、燃油、机油、液压等多场景过滤系统，服务全球汽车、重型车辆、工业设备、航空航天领域的原厂配套及售后替换市场。
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
ATMU vs BMRN — 直观对比
营收规模更大
BMRN
是对方的2.0倍
$446.6M
营收增速更快
BMRN
高出7.2%
9.8%
净利率更高
ATMU
高出16.1%
-5.3%
自由现金流更多
BMRN
多$27.7M
$31.2M
两年增速更快
BMRN
近两年复合增速
2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $446.6M | $874.6M |
| 净利润 | $48.0M | $-46.6M |
| 毛利率 | 28.5% | 68.5% |
| 营业利润率 | 15.8% | -5.1% |
| 净利率 | 10.7% | -5.3% |
| 营收同比 | 9.8% | 17.0% |
| 净利润同比 | 19.7% | -137.3% |
| 每股收益（稀释后） | $0.58 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATMUBMRN
| Q4 25 | $446.6M | $874.6M | ||
| Q3 25 | $447.7M | $776.1M | ||
| Q2 25 | $453.5M | $825.4M | ||
| Q1 25 | $416.5M | $745.1M | ||
| Q4 24 | $406.7M | $747.3M | ||
| Q3 24 | $403.7M | $745.7M | ||
| Q2 24 | $432.6M | $712.0M | ||
| Q1 24 | $426.6M | $648.8M |
净利润ATMUBMRN
| Q4 25 | $48.0M | $-46.6M | ||
| Q3 25 | $54.8M | $-30.7M | ||
| Q2 25 | $59.9M | $240.5M | ||
| Q1 25 | $44.7M | $185.7M | ||
| Q4 24 | $40.1M | $124.9M | ||
| Q3 24 | $43.8M | $106.1M | ||
| Q2 24 | $56.2M | $107.2M | ||
| Q1 24 | $45.5M | $88.7M |
毛利率ATMUBMRN
| Q4 25 | 28.5% | 68.5% | ||
| Q3 25 | 28.9% | 82.0% | ||
| Q2 25 | 28.9% | 81.8% | ||
| Q1 25 | 26.5% | 79.7% | ||
| Q4 24 | 26.3% | 81.8% | ||
| Q3 24 | 27.6% | 74.7% | ||
| Q2 24 | 30.5% | 81.7% | ||
| Q1 24 | 26.2% | 80.7% |
营业利润率ATMUBMRN
| Q4 25 | 15.8% | -5.1% | ||
| Q3 25 | 18.3% | -6.0% | ||
| Q2 25 | 18.0% | 33.5% | ||
| Q1 25 | 15.6% | 30.0% | ||
| Q4 24 | 13.4% | 21.6% | ||
| Q3 24 | 15.7% | 15.3% | ||
| Q2 24 | 18.4% | 16.9% | ||
| Q1 24 | 16.1% | 13.6% |
净利率ATMUBMRN
| Q4 25 | 10.7% | -5.3% | ||
| Q3 25 | 12.2% | -4.0% | ||
| Q2 25 | 13.2% | 29.1% | ||
| Q1 25 | 10.7% | 24.9% | ||
| Q4 24 | 9.9% | 16.7% | ||
| Q3 24 | 10.8% | 14.2% | ||
| Q2 24 | 13.0% | 15.1% | ||
| Q1 24 | 10.7% | 13.7% |
每股收益（稀释后）ATMUBMRN
| Q4 25 | $0.58 | $-0.22 | ||
| Q3 25 | $0.66 | $-0.16 | ||
| Q2 25 | $0.72 | $1.23 | ||
| Q1 25 | $0.54 | $0.95 | ||
| Q4 24 | $0.49 | $0.65 | ||
| Q3 24 | $0.52 | $0.55 | ||
| Q2 24 | $0.67 | $0.55 | ||
| Q1 24 | $0.54 | $0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $236.4M | $1.3B |
| 总债务越低越好 | $570.0M | — |
| 股东权益账面价值 | $378.5M | $6.1B |
| 总资产 | $1.4B | $7.6B |
| 负债/权益比越低杠杆越低 | 1.51× | — |
8季度趋势，按日历期对齐
现金及短期投资ATMUBMRN
| Q4 25 | $236.4M | $1.3B | ||
| Q3 25 | $218.3M | $1.3B | ||
| Q2 25 | $190.8M | $1.2B | ||
| Q1 25 | $183.3M | $1.0B | ||
| Q4 24 | $184.3M | $942.8M | ||
| Q3 24 | $196.8M | $675.4M | ||
| Q2 24 | $160.5M | $972.1M | ||
| Q1 24 | $149.2M | $747.0M |
总债务ATMUBMRN
| Q4 25 | $570.0M | — | ||
| Q3 25 | $577.5M | — | ||
| Q2 25 | $585.0M | — | ||
| Q1 25 | $588.8M | — | ||
| Q4 24 | $592.5M | — | ||
| Q3 24 | $596.2M | — | ||
| Q2 24 | $600.0M | — | ||
| Q1 24 | $600.0M | — |
股东权益ATMUBMRN
| Q4 25 | $378.5M | $6.1B | ||
| Q3 25 | $336.7M | $6.1B | ||
| Q2 25 | $316.3M | $6.0B | ||
| Q1 25 | $265.3M | $5.8B | ||
| Q4 24 | $227.4M | $5.7B | ||
| Q3 24 | $221.2M | $5.4B | ||
| Q2 24 | $178.1M | $5.3B | ||
| Q1 24 | $121.8M | $5.1B |
总资产ATMUBMRN
| Q4 25 | $1.4B | $7.6B | ||
| Q3 25 | $1.3B | $7.6B | ||
| Q2 25 | $1.3B | $7.5B | ||
| Q1 25 | $1.2B | $7.1B | ||
| Q4 24 | $1.2B | $7.0B | ||
| Q3 24 | $1.2B | $6.9B | ||
| Q2 24 | $1.2B | $7.1B | ||
| Q1 24 | $1.1B | $6.9B |
负债/权益比ATMUBMRN
| Q4 25 | 1.51× | — | ||
| Q3 25 | 1.72× | — | ||
| Q2 25 | 1.85× | — | ||
| Q1 25 | 2.22× | — | ||
| Q4 24 | 2.61× | — | ||
| Q3 24 | 2.70× | — | ||
| Q2 24 | 3.37× | — | ||
| Q1 24 | 4.93× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $47.5M | $99.6M |
| 自由现金流经营现金流 - 资本支出 | $31.2M | $58.9M |
| 自由现金流率自由现金流/营收 | 7.0% | 6.7% |
| 资本支出强度资本支出/营收 | 3.6% | 4.7% |
| 现金转化率经营现金流/净利润 | 0.99× | — |
| 过去12个月自由现金流最近4个季度 | $148.8M | $725.0M |
8季度趋势，按日历期对齐
经营现金流ATMUBMRN
| Q4 25 | $47.5M | $99.6M | ||
| Q3 25 | $82.1M | $368.7M | ||
| Q2 25 | $44.4M | $185.3M | ||
| Q1 25 | $28.7M | $174.4M | ||
| Q4 24 | $20.0M | $185.6M | ||
| Q3 24 | $70.7M | $221.5M | ||
| Q2 24 | $22.9M | $118.8M | ||
| Q1 24 | $-8.2M | $47.0M |
自由现金流ATMUBMRN
| Q4 25 | $31.2M | $58.9M | ||
| Q3 25 | $68.9M | $340.2M | ||
| Q2 25 | $32.4M | $168.2M | ||
| Q1 25 | $16.3M | $157.6M | ||
| Q4 24 | $10.0M | $166.1M | ||
| Q3 24 | $54.3M | $203.0M | ||
| Q2 24 | $11.3M | $97.4M | ||
| Q1 24 | $-18.8M | $20.9M |
自由现金流率ATMUBMRN
| Q4 25 | 7.0% | 6.7% | ||
| Q3 25 | 15.4% | 43.8% | ||
| Q2 25 | 7.1% | 20.4% | ||
| Q1 25 | 3.9% | 21.2% | ||
| Q4 24 | 2.5% | 22.2% | ||
| Q3 24 | 13.5% | 27.2% | ||
| Q2 24 | 2.6% | 13.7% | ||
| Q1 24 | -4.4% | 3.2% |
资本支出强度ATMUBMRN
| Q4 25 | 3.6% | 4.7% | ||
| Q3 25 | 2.9% | 3.7% | ||
| Q2 25 | 2.6% | 2.1% | ||
| Q1 25 | 3.0% | 2.3% | ||
| Q4 24 | 2.5% | 2.6% | ||
| Q3 24 | 4.1% | 2.5% | ||
| Q2 24 | 2.7% | 3.0% | ||
| Q1 24 | 2.5% | 4.0% |
现金转化率ATMUBMRN
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.50× | — | ||
| Q2 25 | 0.74× | 0.77× | ||
| Q1 25 | 0.64× | 0.94× | ||
| Q4 24 | 0.50× | 1.49× | ||
| Q3 24 | 1.61× | 2.09× | ||
| Q2 24 | 0.41× | 1.11× | ||
| Q1 24 | -0.18× | 0.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATMU
| Fuel Products | $219.1M | 49% |
| Lube | $84.8M | 19% |
| Air | $74.0M | 17% |
| Other | $68.7M | 15% |
| Related Party | $14.9M | 3% |
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
